Movement Alert｜TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%

Market Focus08-03

On August 3, TG Therapeutics declined 5.35% in regular trading, trading at $47.415/share, with turnover of approximately $43.75 million.

The decline was triggered by the company's second quarter earnings report, which revealed EPS of $0.05 versus analyst consensus estimates of $0.31–$0.33, representing a miss of approximately 85%. This marks a 70.59% decrease from EPS of $0.17 in the year-ago period. Notably, this is the third consecutive quarter in which EPS has significantly missed expectations, intensifying market concerns over the company's expense control and profitability trajectory.

While revenue of approximately $240 million exceeded the $229.7 million estimate and the company raised full-year BRIUMVI revenue guidance, the top-line beat failed to offset persistent weakness on the earnings front. The widening gap between strong commercial traction for BRIUMVI and bottom-line underperformance suggests elevated spending that investors are increasingly unwilling to overlook.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its core product BRIUMVI is approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140508089?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140508089","market":"hk","top_or_hot":-1,"title":"Movement Alert｜TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%","media":"Market Focus","content":"<p><p>On August 3, TG Therapeutics declined 5.35% in regular trading, trading at $47.415/share, with turnover of approximately $43.75 million.</p><p>The decline was triggered by the company's second quarter earnings report, which revealed EPS of $0.05 versus analyst consensus estimates of $0.31–$0.33, representing a miss of approximately 85%. This marks a 70.59% decrease from EPS of $0.17 in the year-ago period. Notably, this is the third consecutive quarter in which EPS has significantly missed expectations, intensifying market concerns over the company's expense control and profitability trajectory.</p><p>While revenue of approximately $240 million exceeded the $229.7 million estimate and the company raised full-year BRIUMVI revenue guidance, the top-line beat failed to offset persistent weakness on the earnings front. The widening gap between strong commercial traction for BRIUMVI and bottom-line underperformance suggests elevated spending that investors are increasingly unwilling to overlook.</p><p>TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its core product BRIUMVI is approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜TG Therapeutics Falls 5.35% in Regular Trading, Q2 EPS Misses Estimates by 85%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, TG Therapeutics declined 5.35% in regular trading, trading at $47.415/share, with turnover of approximately $43.75 million.</p><p>The decline was triggered by the company's second quarter earnings report, which revealed EPS of $0.05 versus analyst consensus estimates of $0.31–$0.33, representing a miss of approximately 85%. This marks a 70.59% decrease from EPS of $0.17 in the year-ago period. Notably, this is the third consecutive quarter in which EPS has significantly missed expectations, intensifying market concerns over the company's expense control and profitability trajectory.</p><p>While revenue of approximately $240 million exceeded the $229.7 million estimate and the company raised full-year BRIUMVI revenue guidance, the top-line beat failed to offset persistent weakness on the earnings front. The widening gap between strong commercial traction for BRIUMVI and bottom-line underperformance suggests elevated spending that investors are increasingly unwilling to overlook.</p><p>TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its core product BRIUMVI is approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1140508089","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140508089","pubTimestamp":1785765247,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, TG Therapeutics declined 5.35% in regular trading, trading at $47.415/share, with turnover of approximately $43.75 million.The decline was triggered by the company's second quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"走势警报|TG Therapeutics 常规交易下跌 5.35%，第二季度每股收益低于预期 85%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"On August 3, TG Therapeutics declined 5.35% in regular trading, trading at $47.415/share, with turnover of approximately $43.75 million.The decline was triggered by the company's second quarter earnings report, which revealed EPS of $0.05 versus analyst consensus estimates of $0.31–$0.33, representing a miss of approximately 85%. This marks a 70.59% decrease from EPS of $0.17 in the year-ago period. Notably, this is the third consecutive quarter in which EPS has significantly missed expectations, intensifying market concerns over the company's expense control and profitability trajectory.While revenue of approximately $240 million exceeded the $229.7 million estimate and the company raised full-year BRIUMVI revenue guidance, the top-line beat failed to offset persistent weakness on the earnings front. The widening gap between strong commercial traction for BRIUMVI and bottom-line underperformance suggests elevated spending that investors are increasingly unwilling to overlook.TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its core product BRIUMVI is approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140508089","isCrawlerRequest":true}